The reports of my death have been greatly exaggerated. Mark Twain In July, we summarized the issue of companies acquiring other companies in tax-friendly countries. These so-called "inversions" were not…
Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will…
What do companies such as Twitter, Facebook, and Google have in common with Pfizer, Amgen, BioMarin, Alkermes, and Jazz Pharmaceuticals? Dublin. All of them have set up international operations in Dublin, in…
Yesterday's Financial Times reported that pharmacists in Spain are struggling to continue operating their businesses due to a lack of payment from the Regional governments. “We depend 80 to 90…
Today's New England Journal of Medicine contains a short article by Kozlowski et al entitled Developing the Nation's Biosimilars Program (link to PDF). Here, the authors attempt t provide a…
This week we learn that two novel pain medications will never see the light of day: Novartis had reached the market with the COX-II inhibitor Prexige (rebranded as the unusually…
This weekend was spent attending the Natural Products ExpoWest convention in Anaheim on behalf of a few of our clients. This was our first time attending this conference. Aside from…
The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil,…
Earlier this week we wrote about the emerging trend of increasing state government involvement in the pharmaceutical industry. Today we learn about what the government in Brazil is doing. Of…